<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications</dc:title>
  <dc:creator>/Jourdain, Gonzague</dc:creator>
  <dc:creator>/Ngo-Giang-Huong, Nicole</dc:creator>
  <dc:creator>Khamduang, W.</dc:creator>
  <dc:subject>hepatitis B</dc:subject>
  <dc:subject>mother-to-child transmission</dc:subject>
  <dc:subject>prevention</dc:subject>
  <dc:subject>antiviral</dc:subject>
  <dc:subject>resistance</dc:subject>
  <dc:description>There is currently no cure for hepatitis B chronic infections. Because new hepatitis B infections result mainly from perinatal transmission, preventing mother-to-child transmission is essential to reach by 2030 the goal of hepatitis B elimination set by the World Health Organization. The universal administration of hepatitis B vaccine to all infants, regardless of maternal status, starting with the birth dose, is the cornerstone of the strategy for elimination. Additional interventions, such as hepatitis B immune globulin administered to newborns and antiviral prophylaxis administered to hepatitis B infected pregnant women, may contribute to reaching the goal earlier. Hepatitis B immune globulin may remain out for reach of many pregnant women in low-and middle-income countries due to cost and logistic issues, but antivirals are cheap and do not require a cold chain for distribution. However, it has been observed that some viruses harbor mutations associated with escape from vaccine-elicited antibodies following immunization or administration of hepatitis B immune globulin. Also, resistance associated mutations have been described for several drugs used for treatment of hepatitis B infected patients as well as for the prevention of mother-to-child transmission. Whether these mutations have the potential to compromise the prevention of mother-to-child transmission or future treatment of the mother is a question of importance. We propose a review of important recent studies assessing tenofovir disoproxil fumarate for the prevention of mother-to-child transmission, and provides detailed information on the mutations possibly relevant in this setting.</dc:description>
  <dc:date>2019</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010075690</dc:identifier>
  <dc:identifier>fdi:010075690</dc:identifier>
  <dc:identifier>Jourdain Gonzague, Ngo-Giang-Huong Nicole, Khamduang W.. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. 2019, 12,  977-987</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>MONDE</dc:coverage>
  <dc:coverage>THAILANDE</dc:coverage>
  <dc:coverage>CHINE</dc:coverage>
</oai_dc:dc>
